Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [2][3]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance than the market, with the Shenwan Beauty Care Index rising by 2.6% from December 31, 2025, to January 9, 2026, which is lower than the Shenwan A Index by 2.8 percentage points [3][4]. - 毛戈平 has initiated an international strategic partnership with L Catterton, focusing on global market expansion, acquisitions, and strategic investments, which is expected to enhance its high-end retail channels and operational optimization [9][21]. - Recent approvals for products such as 爱美客's botulinum toxin and 奇璞生物's collagen implant highlight the ongoing advancements in the medical beauty supply chain, supporting diversified competition in 2026 [9][22][23]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with specific indices showing lower growth rates compared to the overall market [3][4]. - The top-performing stocks in the sector include 力合科创 (+14.7%), 毛戈平 (+8.6%), and 水羊股份 (+7.6%), while the worst performers were 嘉亨家化 (-3.9%) and 百亚股份 (-2.8%) [5]. Recent Developments - 毛戈平's strategic partnership with L Catterton aims to enhance its brand's global presence and operational capabilities [9][21]. - The approval of 爱美客's botulinum toxin and 奇璞生物's collagen implant signifies a robust supply chain in the medical beauty sector [22][23]. Investment Recommendations - Recommended companies include 毛戈平, 上美股份, and 上海家化 for their strong brand matrices and growth potential. Companies like 爱美客 and 朗姿股份 are highlighted for their strong profitability and product pipeline [3][10]. - The report suggests focusing on companies with high R&D barriers and strong profitability in the upstream medical beauty segment [3][10].

Group 1 - The core viewpoint of the article is that Guosen Securities has given a "better than market" rating to Aimeike (300896.SZ) based on recent developments in its product pipeline and market potential [1] - Aimeike's exclusive distribution of Huons BioPharma's injectable botulinum toxin product has received regulatory approval for sale in China, including Hong Kong and Macau, filling a gap in its product line [1] - The company is expected to enhance its core competitiveness by offering comprehensive solutions through the combination of new and existing products, with ongoing research and development in weight management and submental fat products [1] Group 2 - The medical aesthetics consumption penetration rate still has significant room for improvement, indicating potential growth opportunities for the industry [1] - Aimeike is investing in self-research to develop new product lines while also pursuing mergers and acquisitions to enrich its product pipeline and expand international business [1] - The company’s performance growth is supported by these strategies, although there are potential risks related to project progress and market competition [1]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights the successful IPO of Shaanxi Tourism, which leverages its rich tourism resources and strong operational experience to build competitive advantages through a combination of performance-driven tourism, cable car operations, and dining services [22][24][34] - The report emphasizes the resilience of the cultural tourism industry amid ongoing trends to expand domestic demand and promote consumption, suggesting that Shaanxi Tourism's future growth will be supported by new performance projects and cable car capacity upgrades [36] Summary by Sections Retail and Social Services Market Review - The retail and social services indices rose by 4.23% and 4.71% respectively during the week of January 5 to January 9, 2026, with the Shanghai Composite Index increasing by 3.82% [12][14] - Among the sub-sectors, the supermarket segment showed the highest growth, with an increase of 8.18% year-to-date [15][17] Industry Dynamics: Shaanxi Tourism - Shaanxi Tourism, a leading regional tourism company, successfully listed on the Shanghai Stock Exchange on January 6, 2026, becoming the first A-share listed company of the year [22] - The company reported significant revenue contributions from its tourism performance and cable car operations, with a net profit margin and gross profit margin remaining high post-pandemic [24][27] - Revenue breakdown for the first half of 2025 shows that tourism performance accounted for 60.2%, cable car operations for 35.8%, and dining services for 4.0% [24] Investment Recommendations - The report recommends focusing on high-end gold and fashion jewelry brands, highlighting companies like Chow Tai Fook and Chao Hong Ji, which are expected to benefit from market trends [39] - It also suggests monitoring offline retail companies adapting to market changes and AI-enabled cross-border e-commerce leaders, with specific recommendations for Yonghui Supermarket and Aiying Room [39] - In the cosmetics sector, the report emphasizes brands that capture emotional value and innovate with safe ingredients, recommending companies like Mao Ge Ping and Proya [40]

Investment Rating - The industry investment rating is "Positive" (首次) [1] Core Insights - The beauty and personal care industry is experiencing a mixed performance, with the beauty care index declining by 1.70% in December 2025, ranking 24th among all primary industries [15] - The medical beauty sector is seeing innovation with the approval of new products, such as the cross-linked recombinant collagen implant by Jiangsu Chuangjian Medical Technology Co., which is expected to inject new momentum into the market [7][34] - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic high-end skincare brands [8][39] Summary by Sections Market Review - In December, the beauty care index reported a decline of 1.70%, underperforming the broader market, which saw the Shanghai Composite Index increase by 2.06% [15] - For the entire year of 2025, the beauty care index showed a cumulative increase of 0.39%, again lagging behind the Shanghai Composite Index's 18.41% growth [15] Medical Beauty - Jiangsu Chuangjian Medical's cross-linked recombinant collagen implant has been approved, making it the fifth such product in China and the first cross-linked version [34] - The industry is shifting from single product competition to a full-chain layout, with companies like Jinjian Biological and Junzi Biological also making significant advancements in the recombinant collagen space [34][36] Cosmetics - Lin Qingxuan has established itself as a leader in the high-end domestic skincare market, achieving the highest retail sales among domestic brands in 2024 [39] - The company has built a comprehensive supply chain and employs an OMO (Online-Merge-Offline) model to enhance customer engagement and sales [39][49] - Lin Qingxuan's core product, the camellia oil essence, has a high repurchase rate of 33.5%, indicating strong customer loyalty [51] Investment Recommendations - The report recommends focusing on differentiated upstream medical beauty product manufacturers and chain medical beauty institutions, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][53] - In cosmetics, the report suggests investing in brands that innovate in emotional value and safe ingredients, with a focus on domestic brands like Maogeping and Lin Qingxuan [54]

Group 1 - The core point of the article is that Aimeike Technology Development Co., Ltd. has received approval from the National Medical Products Administration for the injection of type A botulinum toxin produced by Huons BioPharma Co., Ltd., marking a significant milestone in the company's strategic layout [1] - The approved product, with a specification of 100U per bottle, has a registration certificate valid until January 4, 2031, which will enable the company to provide more comprehensive solutions to its customers [1] - The import and sales of the product are subject to uncertainties due to domestic and international regulations, market conditions, and exchange rate fluctuations, which may affect the execution of the distribution agreement [1]

Core Viewpoint - The approval of the injectable type A botulinum toxin product from Huons BioPharma marks a significant milestone for the company, enhancing its strategic positioning in the competitive Chinese medical aesthetics market, which is characterized by a growing number of similar products [2][3]. Group 1: Company Developments - The company has been seeking new growth avenues beyond its core hyaluronic acid business, with the injectable botulinum toxin being one of its earliest product initiatives [2]. - The company signed an exclusive agency agreement with Huons Global in September 2018, which was later deepened by acquiring a 25.4% stake in Huons BP in June 2021 [3]. - The recent approval is expected to enrich the company's product matrix and allow for comprehensive solutions for clients, aligning with market expectations for product pricing and positioning [3][6]. Group 2: Market Context - The Chinese medical aesthetics market has seen significant changes over the past seven years, with the number of approved botulinum toxin products increasing to seven, including the newly approved product from Huons BP [7]. - The market was previously dominated by two brands, Botox and Hengli, which held a combined market share of 100% until recent years [7]. - The current market dynamics indicate that while new entrants may face challenges due to intense competition and price pressures, there is still potential for growth, particularly in the mid-to-high-end market segment [9]. Group 3: Stock Market Reaction - Following the announcement of the product approval, the company's stock price rose by 2.69%, reflecting positive market sentiment [5].

Core Insights - The article highlights the significant application value of recombinant human hyaluronidase in the medical field, particularly in subcutaneous administration combined with antibodies, offering multiple advantages over traditional intravenous delivery [1][7]. Market Overview - The global recombinant human hyaluronidase market is projected to reach USD 799 million by 2024, with a year-on-year growth of 18.4% [1][7]. - North America maintains a leading position in the market due to its mature healthcare system, while the Asia-Pacific region, including China, shows strong growth potential [1][7]. Industry Policies - The Chinese government has implemented various policies to support the development of the pharmaceutical manufacturing industry, including the recombinant human hyaluronidase sector, creating a favorable policy environment for growth [4][5]. Industry Chain - The upstream of the recombinant human hyaluronidase industry includes gene components, host cells, culture media, consumables, and production equipment. The midstream focuses on R&D, production, quality control, and registration, while the downstream encompasses applications in assisted reproduction, antibody drug development, aesthetic medicine, gene therapy, and tumor treatment [5][6]. Development Status - The recombinant human hyaluronidase industry in China is entering a rapid growth phase, with a projected market size of CNY 186 million by 2024, reflecting a year-on-year increase of 143.8%, significantly outpacing the global average [7][8]. - The industry is driven by national innovation policies and increasing clinical demand, with expanding applications in medical aesthetics and tumor treatment [7][8]. Competitive Landscape - Several recombinant human hyaluronidase products have been approved globally, including Halozyme Therapeutics' rHuPH20 and Alteogen's Tergase. Shanghai Baijia Pharmaceutical Co., Ltd. has established a first-mover advantage in China with its KJ017 product, which is currently in the NDA registration stage [9][10]. - Baijia Pharmaceutical's revenue from recombinant human hyaluronidase is expected to reach CNY 3.111 million in 2024, marking a year-on-year growth of 681.7% [9][10]. Development Trends - Future innovations in recombinant human hyaluronidase will focus on optimizing gene engineering technology to enhance product purity and activity, as well as developing long-acting formulations and composite preparations [11][12]. - The application scenarios for recombinant human hyaluronidase are expected to diversify, expanding into targeted tumor therapy, assisted reproduction, and orthopedic disease treatment [11][12]. - Domestic companies are anticipated to accelerate the process of replacing international giants in high-end product areas, supported by policy backing and enhanced R&D capabilities [12].

Core Viewpoint - Aimeike has received approval for its injectable type A botulinum toxin product, marking its first such product and the seventh in China, indicating a strategic expansion into the botulinum toxin market [1][2]. Group 1: Product Development and Market Position - Aimeike's foray into botulinum toxin began in 2021 with the acquisition of a 25.42% stake in Huons BioPharma for 856 million yuan [1]. - The newly approved product is positioned as a conventional offering in a market already populated by six established competitors, including Allergan's Botox and domestic brands like Hengli and LeTibao [2][4]. - The approval of Aimeike's botulinum toxin product is seen as a potential third growth driver for the company, although its market differentiation remains uncertain [2][5]. Group 2: Competitive Landscape - The competitive landscape for botulinum toxin products is characterized by established players with clear differentiation and market positioning, making it challenging for Aimeike to carve out a unique space [5][6]. - Aimeike's pricing strategy will significantly influence its market performance, as it may need to align closely with mainstream market prices to achieve sales targets [6][7]. - The existing products in the market have established brand loyalty and clinical advantages, particularly Allergan's Botox, which dominates the high-end market with multiple approved indications [6][7]. Group 3: Financial Performance and Market Trends - Aimeike's core products, including Hyaluronic Acid and PLLA-based fillers, have experienced slowing growth, reflecting increased competition in the aesthetic medicine sector [7][10]. - The revenue from Aimeike's Hyaluronic Acid products is projected to decline, with a significant drop of 23.79% expected in the first half of 2025 [13]. - The market for aesthetic injectables is becoming increasingly competitive, with over 40 brands of hyaluronic acid products approved in China, leading to price pressures and declining profit margins [18][19].

证券日报网讯 1月9日，爱美客（300896）在互动平台回答投资者提问时表示，医美行业正从高速增长 向高质量发展转型，各项监管新政策的出台有利于加速行业洗牌与合规化进程。企业竞争不只是产品价 格的竞争，还包括品牌、技术与服务、行业整合能力等因素。公司将通过不断提升核心竞争力，优化客 户服务，推进公司业务的稳定可持续发展。 ...

证券日报网讯 1月9日，爱美客在互动平台回答投资者提问时表示，公司美格鲁肽注射液项目目前处于 临床试验阶段。公司研发项目相关情况可查阅公司《2025年半年度报告》中"研发项目进展"部分。 （文章来源：证券日报） ...